Current Edition


With more than 70 years’ experience in medical devices, Owen Mumford Pharmaceutical Services is a division of Owen Mumford, with the Head Office located in Woodstock, UK. Our global presence spans from manufacturing facilities in the UK and Malaysia to subsidiaries in the US, Germany and France.

Owen Mumford Pharmaceutical Services specialises in the design, development and manufacture of injectable drug delivery systems for the pharmaceutical, biotech and generics industries. Our trusted devices are used daily in the delivery of various medications for a multitude of conditions across the globe.

Our product portfolio includes single and multi-dose reusable and disposable auto-injectors, pens, and syringes for subcutaneous and intramuscular administration. Our flagship products include UniSafe® platform, a spring-free, passive safety device for 1ml and 2.25ml pre-filled syringes. UniSafe 1mL has regulatory approval as a combination product in Asia and Europe where it is also in patient use.

Our most recent innovation is the 2-step disposable auto-injector Aidaptus®. Aidaptus can be used for both 1mL and 2.25mL syringes in the same base device. It can also readily adapt to different fill volumes using auto-adjust plunger technology providing a solution for formulation changes during development and lifecycle management.


We are proud to have been awarded a distinction in the prestigious Red Dot awards for innovative product design 2023 for Aidaptus.


Aidaptus has an innovative, patient-centric design with automatic needle insertion that provides a simple and consistent user experience. The stopper sensing technology, coupled with the independent, two-phase needle insertion and drug delivery, significantly reduces any impact forces on the syringe, mitigating the risk of syringe breakages during use. With a needle that is shielded before, during and after use, Aidaptus provides reassurance to users who are new to auto-injectors as well as those who experience needle phobia. It can also give users confidence that the injection has been successfully completed with an audible notification at the start and end of the procedure.

Owen Mumford Pharmaceutical Services has an exclusive agreement with Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions. Stevanato Group is our manufacturing partner for the Aidaptus auto-injector moulding the components for the device and also providing final and sub-assembly equipment.  Our collaboration aims to reduce supply chain complexity and reduce risk in combination product development for our pharmaceutical partners.

Owen Mumford Pharmaceutical Services also has an alliance with Noble International providing patient-focused training devices and for both UniSafe® and Aidaptus.

Our products are supported by our services, and we work with our pharmaceutical partners every step of the way, supporting and them throughout their combination product development.

For more information, please visit our website: